NCT03858270

Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

Status unknown Phase 3 Last updated 1 July 2020

What this trial tests

Phase 3 trial testing Memantine in Parkinson Disease in 50 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
1 April 2022

1 July 2023

Quick facts

Lead sponsor	Wayne State University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	1 April 2019
Primary completion	1 April 2022
Estimated completion	1 July 2023
Sites	1 location across United States

Drugs / interventions tested

• Memantine (MEMANTINE) — full drug profile →
• Placebo

Conditions studied

• Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Wayne State University

Who can join

Adults 45 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's Disease. Dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging. With Lewy Body Dementia, protein deposits, or Lewy Bodies, accumulate in nerve cells throughout the brain, affecting motor control, memory and thinking. LBD can also form with the progression of Parkinson's disease (PD). PD is a degenerative nervous system disorder that affects movement ability. Using more sensitive MRI imaging techniques the investigators are attempting to see if disease progression can be monitored more closely. At the same time, the study medication Memantine will be compared to a placebo to determine if it can be used to slow the progression of PD. The purpose of this study is to assess if disease progression can be better monitored through brain imaging and if Memantine will help slow disease progression.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Therapeutics in the Pipeline Targeting <i>α</i>-Synuclein for Parkinson's Disease.
   Grosso Jasutkar H, Oh SE, Mouradian MM. · · 2022 · cited 69× · PMID 35017177 · DOI 10.1124/pharmrev.120.000133
2. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
   McFarthing K, Buff S, Rafaloff G, Pitzer K, et al · · 2024 · cited 49× · PMID 39031388 · DOI 10.3233/jpd-240272
3. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.
   Menon S, Armstrong S, Hamzeh A, Visanji NP, et al · · 2022 · cited 49× · PMID 35614915 · DOI 10.3389/fneur.2022.852003
4. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
   McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, et al · · 2021 · cited 46× · PMID 34151864 · DOI 10.3233/jpd-219006
5. Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases.
   Seillier C, Lesept F, Toutirais O, Potzeha F, et al · · 2022 · cited 26× · PMID 36142247 · DOI 10.3390/ijms231810336
6. Recent Advances in the Treatment of Genetic Forms of Parkinson's Disease: Hype or Hope?
   Cavallieri F, Cury RG, Guimarães T, Fioravanti V, et al · · 2023 · cited 14× · PMID 36899899 · DOI 10.3390/cells12050764
7. "Janus-Faced" α-Synuclein: Role in Parkinson's Disease.
   Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, et al · · 2021 · cited 7× · PMID 34124057 · DOI 10.3389/fcell.2021.673395
8. Decoding crosstalk between neurotransmitters and α-synuclein in Parkinson's disease: pathogenesis and therapeutic implications.
   Guan L, Lin L, Ma C, Qiu L. · · 2025 · cited 5× · PMID 40486190 · DOI 10.1177/17562864251339895